J-Pharma Co.
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, J-Pharma Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
J-Pharma Co.: 2 sponsored US clinical trials, 2 recruiting.
J-Pharma Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Biliary Tract Cancer (BTC), with 1 trials.
Mid-pack sponsor footprint
J-Pharma Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
A Study of JPH034 in Healthy Adult Participants
NCT07534657
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
NCT07265674
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the J-Pharma Co. pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Biliary Tract Cancer (BTC) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
J-Pharma Co.: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
J-Pharma Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this J-Pharma Co. page
2 registered trials is a research-attention snapshot, not an endorsement of J-Pharma Co. or any single study.
- 2 of J-Pharma Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Biliary Tract Cancer (BTC) is the condition J-Pharma Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Biliary Tract Cancer (BTC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
J-Pharma Co. pipeline card: 2 registered trials from official public datasets.Report a data error.